Overcoming a barrier to moving forward with clinical trials, which in this case means achieving full funding of Phase 2, DOES add value, derived from the increased likelihood of eventual approval. The hope of today's investors is to sell these shares to people who want them when approval appears in sight, so making authentic progress toward that goal DOES increase value. There is no reason to think they will be able to do that, though. Longs are jumping into an abyss. Issues like getting out of bankruptcy, the "Q" dropping, 8K dropping, getting current, and uplisting to NASDAQ do NOT increase the LIKELIHOOD of their funding Phase 2, and hence have no effect on the share price beyond a day or two of speculative convulsions.
Market Data 
Markets 
AI
